Fully independent intellectual property rights. Kylonova's Multivalent Import Platform (MVIP) is a specific delivery system for hepatic disease treatments constructed using the hepatic parenchymal cells of the Asialoglycoprotein receptor (ASGPR).

General Formula:

（X-L)n-B-D-T 

Wherein:

※        X is a target-specific ligand

※        L is a branch of a sterically stabilized structure

※        B is a connector

※        D is a linker

※        T is a drug

※        n is an integer from 1 to 15

Multivalent Import Platform (MVIP) has the following features:

●  It has been applied to siRNA drugs. Pre-clinical subcutaneous injection test has been finished. It has active liver targeting, stability and good biodegradability.

●  Applicable to small molecule drugs, the pre-clinical intestinal drug administration has been verified, which can avoid the whole-body intake of drugs and reduce the toxic side effects on other organs.

●  Low production costs, can be produced in bulk, and sold commercially.